Jay K. Wathen, Ph.D.

Affiliations: 
2005 The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Statistics, Biostatistics Biology
Google:
"Jay Wathen"

Parents

Sign in to add mentor
Peter F. Thall grad student 2005 The University of Texas Graduate School of Biomedical Sciences at Houston
 (Bayesian doubly optimal group sequential designs for randomized clinical trials.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Wathen JK, Thall PF. (2017) A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clinical Trials (London, England). 14: 432-440
Schuetze SM, Wathen JK, Lucas DR, et al. (2015) SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer
Thall P, Fox P, Wathen J. (2015) Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1621-8
Morgan CC, Huyck S, Jenkins M, et al. (2014) Adaptive Design: Results of 2012 Survey on Perception and Use Therapeutic Innovation and Regulatory Science. 48: 473-481
Hensley ML, Wathen JK, Maki RG, et al. (2013) Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 119: 1555-61
Fox E, Patel S, Wathen JK, et al. (2012) Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. The Oncologist. 17: 321
Parmar S, Andersson BS, Couriel D, et al. (2011) Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 294-302
Chugh R, Wathen JK, Patel SR, et al. (2010) Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4884-91
Chugh R, Wathen JK, Maki RG, et al. (2009) Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3148-53
Berry D, Wathen JK, Newell M. (2009) Bayesian model averaging in meta-analysis: Vitamin E supplementation and mortality Clinical Trials. 6: 28-41
See more...